New drug combination for squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called ALK201 combined with an immunotherapy drug (ivonescimab) for people with squamous non-small cell lung cancer. The goal is to see if this combination can shrink tumors and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a diagnosis of squamous non-small cell lung cancer that is advanced or metastatic.
- You should have tried at least one prior treatment for advanced lung cancer, and your disease has progressed.
- You must be in generally good physical condition (able to do most daily activities).
- You must not have serious or uncontrolled health problems (like severe heart, lung, or kidney disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ALK202, given with other medicines, to see if it is safe and works for people with non-small cell lung cancer. It targets certain proteins on cancer cells, and doctors will check your tumor for those markers to see if you might benefit.
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This trial tests a new combination of three medicines (two chemotherapies and an immunotherapy) for people with a certain type of advanced lung cancer called squamous non-small cell lung cancer. The goal is to see if this combo can help shrink or control the cancer better than current treatments.
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
This trial tests two new drugs—SHR-A1921 and adebrelimab—for people with advanced non-small cell lung cancer (NSCLC) whose cancer has grown after standard first-line treatment. The goal is to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.